CA2746495C - Anti-viral protection with viruses containing a defective genome - Google Patents

Anti-viral protection with viruses containing a defective genome Download PDF

Info

Publication number
CA2746495C
CA2746495C CA2746495A CA2746495A CA2746495C CA 2746495 C CA2746495 C CA 2746495C CA 2746495 A CA2746495 A CA 2746495A CA 2746495 A CA2746495 A CA 2746495A CA 2746495 C CA2746495 C CA 2746495C
Authority
CA
Canada
Prior art keywords
virus
influenza
mice
interferon
infection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2746495A
Other languages
English (en)
French (fr)
Other versions
CA2746495A1 (en
Inventor
Nigel Dimmock
Andrew Easton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Warwick
Original Assignee
University of Warwick
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Warwick filed Critical University of Warwick
Publication of CA2746495A1 publication Critical patent/CA2746495A1/en
Application granted granted Critical
Publication of CA2746495C publication Critical patent/CA2746495C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16161—Methods of inactivation or attenuation
    • C12N2760/16162—Methods of inactivation or attenuation by genetic engineering

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA2746495A 2008-12-12 2009-12-08 Anti-viral protection with viruses containing a defective genome Active CA2746495C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0822672.2A GB0822672D0 (en) 2008-12-12 2008-12-12 Anti-viral protection with viruses containing a defective genome
GB0822672.2 2008-12-12
PCT/GB2009/051666 WO2010067109A1 (en) 2008-12-12 2009-12-08 Anti-viral protection with viruses containing defective genome segments

Publications (2)

Publication Number Publication Date
CA2746495A1 CA2746495A1 (en) 2010-06-17
CA2746495C true CA2746495C (en) 2018-04-17

Family

ID=40325992

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2746495A Active CA2746495C (en) 2008-12-12 2009-12-08 Anti-viral protection with viruses containing a defective genome

Country Status (11)

Country Link
US (1) US8691215B2 (https=)
EP (1) EP2355834B1 (https=)
CN (1) CN102256611B (https=)
AU (1) AU2009326204B2 (https=)
CA (1) CA2746495C (https=)
DK (1) DK2355834T3 (https=)
ES (1) ES2423193T3 (https=)
GB (1) GB0822672D0 (https=)
IN (1) IN2011KN02819A (https=)
PL (1) PL2355834T3 (https=)
WO (1) WO2010067109A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2019685B1 (en) 2006-05-24 2014-11-12 The University Of Warwick Defective interfering virus
GB2522615A (en) * 2014-01-16 2015-08-05 Univ Warwick Assay and medicament
WO2019206285A1 (en) * 2018-04-26 2019-10-31 The University Of Hong Kong Nucleic acid molecules and dual-functional peptides having antiviral activity and delivery activity, compositions and methods thereof
GB202209861D0 (en) * 2022-07-05 2022-08-17 Univ Court Univ St Andrews Viral vectors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8715940B2 (en) 1999-04-06 2014-05-06 Wisconsin Alumni Research Foundation Method of making recombinant influenza virus
JP5147405B2 (ja) 2004-10-06 2013-02-20 メディミューン，エルエルシー 冷蔵温度安定型インフルエンザワクチン組成物
AU2005303817B8 (en) 2004-11-11 2010-09-30 Abbott Biologicals B.V. Defective influenza virus particles
EP2019685B1 (en) 2006-05-24 2014-11-12 The University Of Warwick Defective interfering virus
GB2437799B (en) * 2006-05-24 2008-08-13 Univ Warwick Defective interfering virus

Also Published As

Publication number Publication date
CN102256611A (zh) 2011-11-23
ES2423193T3 (es) 2013-09-18
US8691215B2 (en) 2014-04-08
US20110243896A1 (en) 2011-10-06
AU2009326204A1 (en) 2011-06-23
CA2746495A1 (en) 2010-06-17
DK2355834T3 (da) 2013-07-29
EP2355834B1 (en) 2013-05-01
EP2355834A1 (en) 2011-08-17
WO2010067109A1 (en) 2010-06-17
GB0822672D0 (en) 2009-01-21
PL2355834T3 (pl) 2014-03-31
IN2011KN02819A (https=) 2015-07-10
AU2009326204B2 (en) 2014-01-09
CN102256611B (zh) 2014-05-21

Similar Documents

Publication Publication Date Title
Easton et al. A novel broad-spectrum treatment for respiratory virus infections: influenza-based defective interfering virus provides protection against pneumovirus infection in vivo
Bean et al. Biologic potential of amantadine-resistant influenza A virus in an avian model
Dimmock et al. Defective interfering influenza virus RNAs: time to reevaluate their clinical potential as broad-spectrum antivirals?
US10793834B2 (en) Live-attenuated virus and methods of production and use
Whittaker Intracellular trafficking of influenza virus: clinical implications for molecular medicine
Wiley et al. Emerging Infections of CNS: Avian Influenza A Virus, R ift V alley Fever Virus and Human Parechovirus
García‐Sastre et al. Lessons learned from reconstructing the 1918 influenza pandemic
US9827304B2 (en) Live attenuated vaccines for influenza viruses
CA2746495C (en) Anti-viral protection with viruses containing a defective genome
Mann et al. Interfering vaccine (defective interfering influenza A virus) protects ferrets from influenza, and allows them to develop solid immunity to reinfection
US9089516B2 (en) Method of preventing or treating influenza A viral infection using cloned DI influenza A viral particles
Scott et al. Defective interfering virus protects elderly mice from influenza
Pu et al. Synergism of co-mutation of two amino acid residues in NS1 protein increases the pathogenicity of influenza virus in mice
CN101454023B (zh) 干扰缺损病毒
Donatelli et al. Influenza viruses: structure and interspecies transmission mechanisms
WO2020163768A1 (en) Stabilized 9 and 10 segmented influenza viruses as a vaccine platform and methods of making and using same
US12582708B2 (en) Recombinant influenza viruses comprising truncated NS1 fusion proteins
Ngunjiri Influenza virus noninfectious biologically active particle subpopulations: Detection, quantification, genetic complexity, function and their novel use as an in vitro screen for self-adjuvating live-attenuated influenza vaccines
Webster et al. Antiviral compounds for treatment of highly pathogenic avian influenza
Cauldwell Investigating the mechanisms of influenza polymerase host adaptation
Lipatov et al. Highly lethal H5N1 influenza virus in asia: Genesis and options for control.
Nasser Antiviral activity of influenza virus M1 zinc finger peptides

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20141203

H11 Ip right ceased following rejected request for revival

Free format text: ST27 STATUS EVENT CODE: T-6-6-H10-H11-H101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TIME LIMIT FOR REVERSAL EXPIRED

Effective date: 20250610

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20251103

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251106